Organigram agrees to acquire Aurora Cannabis

By Public Technologies
  • Organigram agreed to acquire Aurora Cannabis in a deal valuing its fully diluted equity at approximately CAD 561 million.
  • Aurora shareholders will receive CAD 7.80 per share in cash, shares or a combination, subject to proration.
  • Financing includes a CAD 187.5 million private placement with BAT and senior secured credit facilities of up to CAD 210 million.
  • The combination is expected to generate more than CAD 50 million in synergies across Canadian and international operations.
  • Closing is expected in January 2027, subject to shareholder, court and regulatory approvals; completion cannot occur before January 6.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OrganiGram Global Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-073513), on November 13, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.